[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"peripheral-neuropathy-hereditary\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:peripheral-neuropathy-hereditary":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":5},"100640793","physical-activity-level-at-home-in-cmt1a-patients-wearable-sensor-assessment-100640793",false,"NCT07591779","Physical Activity Level at Home in CMT1A Patients: Wearable Sensor Assessment","Study of the Relationship Between Clinical and Functional Characteristics of Patients With CMT1A Disease and Their Level of Physical Activity at Home Measured Using Portable Electronic Sensors","CMT1A-HOME","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Genetically confirmed diagnosis of CMT1A (PMP22 duplication on chromosomal analysis)\n3. Followed at the National Reference Centre for Rare Peripheral Neuropathies (Service de Neurologie, CHU de Limoges) and\u002For having undergone gait analysis at the Quantified Movement Analysis Laboratory (Laboratoire d'AQM), Service de Médecine Physique et de Réadaptation, CHU de Limoges\n4. Ability to walk independently (with or without walking aids)\n5. Informed consent obtained\n6. Affiliated to French social security system\n\nExclusion Criteria:\n\n1. Other associated neurological condition that could independently affect walking or motor activity\n2. Inability to wear the sensor device (skin allergy, sensory intolerance)\n3. Inability to comply with study procedures (cognitive impairment, no fixed domicile)\n4. Participation in another interventional study during the same period\n5. Pregnant or breastfeeding women\n6. Patients under legal protection (guardianship or curatorship)","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","OBSERVATIONAL","Charcot-Marie-Tooth disease type 1A (CMT1A) is the most common hereditary peripheral neuropathy, affecting approximately 26,000 patients in France. It presents as chronic and progressive sensorimotor deficits predominantly affecting the distal lower limbs, with onset typically in childhood. There is currently no specific pharmacological treatment; management remains symptomatic.\n\nThis research will:\n\nIn the long run, validated wearable sensors could improve patient follow-up, personalize rehabilitation, and support the design of clinical trials for CMT1A - including trials of the novel \"Nano-Cur\" treatment currently under development.",[25,26,27,28,29],"Charcot-Marie-Tooth Disease, Type IA","Peripheral Neuropathy Hereditary","Motor Activity","Walking, Difficulty","Neuromuscular Diseases",[31,32,33,34,35,36,37],"CMT1A","wearable sensor","actigraphy","physical activity","CMT-FOM","functional assessment","peripheral neuropathy","NOT_YET_RECRUITING","2026-05-20",{"date":41,"type":42},"2026-05-22","ACTUAL",{"date":44,"type":21},"2026-06-01",{"date":46,"type":21},"2027-06-30",{"name":48,"class":49},"University Hospital, Limoges","OTHER"]